Argenx Se: Strategic Focus and Growth Potential in Graves’ Disease Treatment Justifies Buy Rating

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Argenx Se today and set a price target of $915.00.

Douglas Tsao has given his Buy rating due to a combination of factors related to Argenx Se’s strategic focus and potential in the treatment of Graves’ Disease. Despite the discontinuation of the TED program, which was not entirely unexpected due to mixed data from similar studies, the company remains committed to its Vision 2030 plan. This plan includes ambitious goals such as developing five new molecules in Phase 3 and treating 50,000 patients by 2030, indicating strong future growth potential.
Argenx’s management is confident in the efficacy of their FcRn therapy for Graves’ Disease, differentiating it from TED, and plans to initiate a registrational study in early 2026. The valuation of Argenx is supported by a risk-adjusted revenue estimate for 2035, with various pipeline assets adjusted for their probability of success. The company’s strategic use of peer-reviewed data and interim analyses to manage capital efficiently further supports the Buy rating, as it demonstrates prudent management and a focus on long-term success.